Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial

A single‐institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin‐induced acute nausea and vomiting. All patients were chemotherapy‐naïve and treated with cisplatin on Day 1 (80 to 100 mg/m2).

[1]  U. Tirelli,et al.  Ondansetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting , 1995 .

[2]  V. Gebbia,et al.  Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial , 1994, Cancer.

[3]  A. Favero,et al.  Are there differences among the serotonin antagonists? , 1994, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[4]  P. Hesketh.  Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists , 1994, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[5]  B. Hecquet,et al.  5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study , 1994 .

[6]  P. Ruff,et al.  Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study , 1994 .

[7]  A. Favero,et al.  Reducing Chemotherapy-Induced Nausea and Vomiting , 1993, Drug safety.

[8]  J. Verweij,et al.  Are 5HT3 antagonists fully cross-resistant? A pilot experience , 1993 .

[9]  S. Drechsler,et al.  Tropisetron (TRO) VS. ondansetron (OND) in prophylaxis of chemotherapy-induced emesis (CIE) , 1993 .

[10]  V. Kataja,et al.  5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. , 1993, European journal of cancer.

[11]  Liège,et al.  Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. , 1992, British Journal of Cancer.

[12]  A. Favero,et al.  Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis , 1992 .

[13]  S. Dilly.  Are granisetron and ondansetron equivalent in the clinic? , 1992, European journal of cancer.

[14]  M. Tonato,et al.  Methodology of antiemetic trials: a review. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Serraino,et al.  Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Cubeddu,et al.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. , 1990, The New England journal of medicine.

[17]  R. Joss,et al.  The symptomatic control of cytostatic drug-induced emesis. A recent history and review. , 1990, European journal of cancer.

[18]  M. Soukop.  A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. , 1990, European journal of cancer.

[19]  S. Barni,et al.  The biological significance of soluble interleukin-2 receptors in solid tumors. , 1990, European journal of cancer.

[20]  B. Chevallier.  Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. , 1990, European journal of cancer.

[21]  I. Smith.  A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group. , 1990, European Journal of Cancer.

[22]  F. di Costanzo,et al.  Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Sanger,et al.  Neuropharmacology of emesis induced by anti-cancer therapy. , 1988, Trends in pharmacological sciences.

[24]  R. Simon,et al.  Antiemetic studies: a methodological discussion. , 1986, Cancer treatment reports.

[25]  M. Tonato,et al.  Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. , 1985, Cancer treatment reports.

[26]  S. Groshen,et al.  Improved control of cisplatin‐induced emesis with high‐dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients , 1985, Cancer.

[27]  A. Willan,et al.  Methodologic issues in trials of antiemetics. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T C Chalmers,et al.  Bias in treatment assignment in controlled clinical trials. , 1983, The New England journal of medicine.

[29]  T. Walsh.  ANTIEMETIC DRUG COMBINATIONS IN ADVANCED CANCER , 1982, The Lancet.

[30]  Whitehead Vm.  Letter: Cancer treatment needs better antiemetics. , 1975 .